Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 4/20 | 0.38 |
| ▸ | KDR | P35968 | 4/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.37 |
| ▸ | LPAR5 | Q9H1C0 | 5/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
| ▸ | FLT4 | P35916 | 1/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RNF4 | P78317 | 1/20 | 0.34 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1259495 | 0.86 | RNF4 (0.46) | RAB9ANPC1RNF4SERPINE1 | |
| SCHEMBL1259022 | 0.85 | MAPK14 (0.34) | KDRMAPK14LPAR1LPAR5RAB9A | |
| SCHEMBL1259999 | 0.83 | KDR (0.57) | METKDRFLT1FLT4ROCK2 | |
| SCHEMBL1259043 | 0.80 | CDK8 (0.41) | METMAPK14LPAR1LPAR5PDK1 | |
| SCHEMBL12892593 | 0.77 | MET (0.46) | METKDRFLT1FLT4RAB9A | |
| SCHEMBL14949663 | 0.75 | MET (0.49) | METKDRFLT1FLT4 | |
| SCHEMBL1258227 | 0.73 | ALDH1A1 (0.40) | LPAR1LPAR5PDK1 | |
| SCHEMBL1258225 | 0.73 | ALDH1A1 (0.40) | LPAR1LPAR5PDK1 | |
| SCHEMBL1258044 | 0.69 | NR3C1 (0.37) | RAB9A | |
| SCHEMBL1258045 | 0.69 | NR3C1 (0.37) | RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046169-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-24 | — | — | US | disclosed |
| WO-2009136663-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046169-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | ABL1, MAP4K2, MAP3K20 | MET 560/4885KDR 966/4885MAPK14 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.